Related references
Note: Only part of the references are listed.Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages
Aravind T. Reddy et al.
FASEB JOURNAL (2014)
Invading one step at a time: the role of invadopodia in tumor metastasis
H. Paz et al.
ONCOGENE (2014)
Collagen as a double-edged sword in tumor progression
Min Fang et al.
TUMOR BIOLOGY (2014)
Small Cell Lung Cancer
Gregory P. Kalemkerian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Pioglitazone Prevents Smoking Carcinogen-Induced Lung Tumor Development in Mice
M. -Y. Li et al.
CURRENT CANCER DRUG TARGETS (2012)
The tumor microenvironment at a glance
Frances R. Balkwill et al.
JOURNAL OF CELL SCIENCE (2012)
Expression of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ) in Human Non-small Cell Lung Carcinoma: Correlation with Clinicopathological Parameters, Proliferation and Apoptosis Related Molecules and Patients' Survival
Costantinos Giaginis et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
PPARγ Expression and Function in Mycobacterial Infection: Roles in Lipid Metabolism, Immunity, and Bacterial Killing
Patricia E. Almeida et al.
PPAR RESEARCH (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Molecular cross-regulation between PPAR-γ and other signaling pathways: Implications for lung cancer therapy
Ajaya Kumar Reka et al.
LUNG CANCER (2011)
TGF-β Signaling and the Role of Inhibitory Smads in Non-small Cell Lung Cancer
Hyo-Sung Jeon et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Chemopreventive Effects of Pioglitazone on Chemically Induced Lung Carcinogenesis in Mice
Yian Wang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition
Ajaya Kumar Reka et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression
Masayuki Shimoda et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2010)
Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model
Christopher M. Lyon et al.
CARCINOGENESIS (2009)
PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis
Jami E. Milam et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2008)
Molecular recognition of nitrated fatty acids by PPARγ
Yong Li et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
PPARs Mediate Lipid Signaling in Inflammation and Cancer
Liliane Michalik et al.
PPAR RESEARCH (2008)
The Role of PPARs in Cancer
Keisuke Tachibana et al.
PPAR RESEARCH (2008)
Chemotherapeutic drugs induce PPAR-Y expression and show sequence-specific synergy with PPAR-Y ligands in inhibition of non-small cell lung cancer
Rajuc C. Reddy et al.
NEOPLASIA (2008)
Synergy between PPARγ ligands and platinum-based drugs in cancer
Geoffrey D. Girnun et al.
CANCER CELL (2007)
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Rangaswamy Govindarajan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Peroxisome Proliferator-Activated Receptors in Lung Cancer
Venkateshwar G. Keshamouni et al.
PPAR RESEARCH (2007)
Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-γ- and ERK-dependent in human non-small lung cancer cells
Mingyue Li et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Differential protein expression profiling by iTRAO-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype
VG Keshamouni et al.
JOURNAL OF PROTEOME RESEARCH (2006)
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone
CJ Yao et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
PPAR-γ agonist increase gefitinib's antitumor activity through PTEN expression
SY Lee et al.
LUNG CANCER (2006)
Rosiglitazone suppresses human lung carcinoma cell growth through PPAR-γ-dependent and PPARγ-independent signal pathways
SW Han et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Activation of peroxisome proliferator-activated receptor-γ by troglitazone (TGZ) inhibits human lung cell growth
MY Li et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Peroxisome proliferator-activated receptor-γ ligands suppress fibronectin gene expression in human lung carcinoma cells:: involvement of both CRE and Sp1
SW Han et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
Pioglitazone attenuates TGF-β1-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)γ
A Maeda et al.
CELL BIOLOGY INTERNATIONAL (2005)
PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production:: implications for therapy of lung fibrosis
HA Burgess et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer
VG Keshamouni et al.
NEOPLASIA (2005)
Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)
Y Bren-Mattison et al.
ONCOGENE (2005)
An overview on biological mechanisms of PPARs
BP Kota et al.
PHARMACOLOGICAL RESEARCH (2005)
Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells
SW Han et al.
CLINICAL CANCER RESEARCH (2004)
Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer
VG Keshamouni et al.
ONCOGENE (2004)
Integrin signalling during tumour progression
WJ Guo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Peroxisome-proliferator-activated receptors and cancers: Complex stories
L Michalik et al.
NATURE REVIEWS CANCER (2004)
Principles for modulation of the nuclear receptor superfamily
H Gronemeyer et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor gamma in non-small cell lung carcinoma
TW Lee et al.
EUROPEAN JOURNAL OF CANCER (2003)
Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth
M Wick et al.
MOLECULAR PHARMACOLOGY (2002)
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
D Panigrahy et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade
S Theocharis et al.
LUNG CANCER (2002)
Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells
T Satoh et al.
ONCOGENE (2002)
Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis
Y Tsubouchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Rational discovery of novel nuclear hormone receptor antagonists
M Schapira et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
